Cigarette smoking is associated with an increased incidence of a number of diseases. Minimal information is available at the molecular level concerning the mechanism of action of cigarette smoke. Platelet-activating (Circulation Research 1992;70:341-347) C igarette smoking is a major risk factor in the development of a number of diseases, including cardiovascular diseases.' The precise biochemical mechanisms by which cigarette smoke causes the various adverse effects are largely unknown. It has been suggested that platelet activation is one of the mechanisms by which the injury associated with the vascular diseases is initiated and/or propagated.2'3 1-0-Alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor [PAF]) is one of the more potent proinflammatory agents known.4 PAF activity was first observed in the middle 1960s as a factor associated with histamine release from leukocytes.5-7 Subsequently, the name was coined to describe a factor released from stimulated basophils.8 The structure was elucidated by DemoFrom the
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PAF-AH Activity Assay
The activity of PAF-AH in plasma was assayed according to the method of Miwa et a126 with minor modifications. The assay mixture contained Tris-HCl (30 mM, pH 7.5), [3H]PAF (50 ,uM, 4.0 ,Ci/,umol) in bovine serum albumin (0.13% final concentration), and various concentrations of plasma in a total volume of 0.5 ml. The assay mixtures and controls (without enzyme) were incubated for 20 minutes at 37°C. The reaction was terminated by addition of 0.5 ml trichloroacetic acid (14%), and the tubes were centrifuged at 3,000g for 5 minutes at 4°C. A 0.1-ml aliquot of the supernatant fraction was mixed with 5 ml scintillation cocktail (Budget-Solve, Research 
Effect of CSE on PAF-AH Activity in Human Plasma
Incubation of human plasma with CSE resulted in marked inhibition of plasma PAF-AH activity (Figure 1A) . As shown in the figure, PAF-AH activity was inhibited by addition of 1,000 ,l CSE to values <5% of the original activity. On the other hand, 98% of the activity remained after a 24-hour incubation at 37°C in the absence of CSE. Thus, the plasma PAF-AH is quite stable under these conditions. Figure 1B illustrates the effect of various concentrations of CSE. As can be seen, 250 gl CSE inhibited -50% of PAF-AH activity when incubated at 37°C for 3 hours. The extract turned to a darker yellow color upon storage, and the inhibitory activity was decreased by 50% when stored at room temperature for 4 days (data not shown). Therefore, the CSE was prepared freshly before each experiment. Cigarette smoke extract (jul) FIGURE 2. Graph showing elimination of platelet-activating factor acetylhydrolase inhibitors in cigarette smoke extract.
Smoke from one cigarette was passed through 1 ml of 10 mM sodium phosphate buffer, pH 7.4, containing 150 mMNaCl by way ofa tubefilled with 50 mg charcoal and glass wool. Extract solution (a) was used after filtration and adjustment ofpH to 7.4 as described in "Materials and Methods. " One milliliter of cigarette smoke extract was treated with 50 mg charcoal and stirredgentlyfor 1 hour. The supematant solution (A) was used after centrifugation at 3, 000g for 5 minutes at room temperature. One hundred microliters of whole plasma was incubated at 37°Cfor 4 hours with various amounts ofnontreated (c) or treated cigarette smoke extract. Values were expressed as a percent of the residual activity (mean±SD) as described in Figure 1 . Significant (p<0.01) inhibition was observed at concentrations of the cigarette smoke extract >100 pd.
Three different brands of cigarettes with filters were examined. Approximately a 50% inhibition in plasma PAF-AH activity was observed when 1,000 1,u of the CSE prepared from filtered cigarettes was used (data not shown). A 90% inhibition was obtained when the nonfiltered cigarettes were used. We have recently compared these findings with the inhibition observed for both filtered (1R4F) and nonfiltered (2R1) research cigarettes (University of Kentucky Research Foundation) and obtained similar results as we observed with the commercial cigarettes. When the CSE was treated with charcoal (50 mg charcoal per cigarette), its inhibitory effects were decreased by 80% (Figure 2 ).
Properties of Inhibition of PAF-AHActivity With CSE
It has been reported that several active oxygen species, such as superoxide anion or hydrogen peroxide, are produced in cigarette smoke and that these species are active in modifying various lipoproteins.18,33 It has been demonstrated that the superoxide anion reacts with LDL to form a more negatively charged species.18 This modified LDL is now readily taken up by macrophages by the scavenger pathway to form foam cells. As previously discussed, PAF-AH is known to be present in the plasma lipoprotein fraction. Therefore, the possible protective effect of SOD and catalase on the activity of plasma PAF-AH in the presence of CSE was examined (Figure 3) . No Figure 1 . A significant (p<0.01) higher residual activity was only found when GSH was used.
inhibition of PAF-AH by CSE, suggesting that redoxactive metal ions such as Cu2`or Fe3", which are known to cause the peroxidation of lipoproteins,18 are not involved in the inhibition. In contrast, the incubation in the presence of increasing concentrations of GSH resulted in the protection of PAF-AH activity against the inhibition caused by CSE (Figure 3) .
To further clarify the beneficial effect of GSH on the inhibition of PAF-AH activity by CSE, we examined other SH-containing compounds, including 2-mercaptoethanol, DYT, and L-cysteine. All these -SH-containing compounds protected against the inhibition caused by the CSE on PAF-AH activity ( Figure 4) . We also examined whether or not other chemicals that are capable of undergoing a redox reaction, such as ascorbate, protected PAF-AH activity in the presence of the CSE. Ascorbate, when added at a concentration of 5-20 mM, did not protect PAF-AH from inhibition by CSE.
In consideration of the effect of the -SH-containing compounds, we examined the possibility that PAF-AH contains active -SH groups. Human plasma was incubated at 37°C for up to 4 hours in the presence of a number of -SH reactive chemicals including p-MBA, NEM, iodoacetamide, or DTNB at concentrations up to 10 mM. As shown in Table 1 , in no instance was there a significant inhibition of PAF-AH. Similar results were obtained when the purified lipoprotein fraction from human plasma was used as the enzyme source.
Reversibility of Inhibition of PAF-AHActivity With CSE Figure 5 illustrates the inhibition of PAF-AH activity by CSE and its partial reversibility by the did not activate PAF-AH activity (data not shown). Based on these observations, it is suggested that the activity of PAF-AH is partially reactivated by the addition of DTT (open bar versus hatched bar) and is protected by the addition of DTT at the beginning of the incubation (crosshatched bar).
Effect of Constituents of Cigarette Smoke
The chemical composition of cigarette smoke has been reported. 34 We have incubated various classes of compounds known to be present in both the gaseous and particulate fractions with the PAF-AH present in plasma in an attempt to identify the chemical nature of the inhibitor. The amount of the various compounds used was 20 times that reported to be present in one cigarette. The compounds incubated were nicotine (438 mM), cotinine (438 mM), propylene glycol (200 mM), palmitic acid (240 mM), catechol (100 mM), hydroquinone (240 mM), furfural (230 mM), indole (5.7 mM), acetaldehyde (910 mM), acrolein (55 mM), acetonitrile (152 mM), hydrazine (42 ,M) , and the heavy metals nickel (75 ,uM) and cadmium (40 MM) . None of the compounds used resulted in an inhibition even at these extremely high concentrations.
Discussion
In the reported experiments we have demonstrated the presence of inhibitor(s) of PAF-AH activity in a CSE. This finding may explain the increase of PAF, a potent proinflammatory agent, in the plasma of smokers.17 It has become apparent that the PAF concentration is regulated not only by its biosynthesis but also by degradation. The latter reaction is catalyzed by PAF-AH in which the biologically active PAF is converted into the inactive lysoPAF. Two isozymes of PAF-AH are known; one is an intracellular enzyme and the other is the plasma enzyme. Farr and colleagues1920 were the first to characterize the plasma enzyme and demonstrated that the plasma form of the enzyme was associated with the lipoprotein fraction and was Ca21 independent and that the preferred substrate for the enzyme contained a short acyl group in the sn-2 position. The different properties and molecular weights of the two isozymes of PAF-AH have been reported. In contrast, the inhibition of PAF-AH by the CSE is not altered by the presence of SOD or catalase (Figure 3) . Therefore, the inhibition by the CSE of the PAF-AH activity and the alteration of the charge of LDL occur at the same site and by different mechanisms. Most probably, the inhibition of PAF-AH activity and the modification of the charge of the LDL fraction is caused by a different component of the CSE. However, a relation between the oxidation of LDL and PAF-AH activity has recently been documented by the observation that oxidized species of phosphatidylcholines are substrates for PAF-AH. 35, 36 The presence of such oxidized phospholipids in plasma has also been described. 37 The peroxidation of LDL has also been reported to be stimulated by Cu2+. 38 The activity of PAF-AH, however, was not altered by the presence of heavy metal chelators such as EDTA (Figure 3) . A variety of SH-containing compounds including GSH, mercaptoethanol, DTT, and cysteine protected the PAF-AH activity from inhibition by the CSE. The GSH concentration in plasma is -1 ,M,39 which is orders of magnitude lower in concentration than that used in the protective and reversal studies reported in this article. The biochemical mechanism by which SH compounds protect and reverse the inhibition of PAF-AH by the CSE may be of minimal importance. We are presently investigating the nature of the inhibition by focusing on the determination of the component in cigarette smoke responsible for the inhibition. There are almost 3,000 components present in cigarette smoke. 34 We have used a representative compound from most of the known groups of compounds present in the particulate and gaseous phases of cigarette smoke to evaluate their effect on PAF-AH activity. The amount of each compound incubated with 10 ,ul serum was 20 times that found in one nonfiltered cigarette. None of the tested compounds inhibited PAF-AH.
The observed inhibition of PAF-AH by a CSE would explain the reported increase in the plasma PAF concentration of smokers.'7 Since PAF is known to be one of the most potent proinflammatory agents described,'12'3 its increase may play an important role in the increased incidence of certain cardiovascular diseases in smokers. 40 In addition, the inhibition of PAF-AH caused by smoking may also contribute to the development of the emphysema associated with smoking. The lower blood pressure found in smokers versus nonsmokers might be explained by the increase in the hypotensive PAF. 41 It is established that women on oral contraceptives are at increased risk of thrombosis. 42 We have previously demonstrated that the activity of plasma PAF-AH is decreased by estrogens. 43 The changes in PAF-AH activity by CSE may also explain why the combination of estrogen intake and smoking leads to at least an additive risk of a thrombotic episode. 42 Although the precise chemical nature of the inhibitor in CSE is yet to be defined, the relation of PAF-AH to cigarette smoking provides a direct bio-chemical link to many of the effects of cigarette smoke on various pathological processes. The determination of the chemical nature and the mechanism of action of the compound in CSE that inhibits PAF-AH activity would be of potential significance.
